PIKE (CT) Blocking Peptide

Home/Control Peptides/PIKE (CT) Blocking Peptide

Pricing & Details

Product No.P222
Protein
PIKE
Formats AvailableView All
Product Type
Blocking Peptide
Alternate Names
Centaurin Gamma 1
Prod No.
Size
Price
Avail.
Qty
Add to cart
P222-50 µg
50 µg
$110.00
In stock
Max:
Min: 1
Step: 1
Contact Us For Academic mAb Advantage Pricing

Antibody Details

Product Details

Reactivity Species
Human
Product Concentration
0.2 mg/ml
Amino Acid Location
15 amino acids near the C-terminus of human PIKE.
Formulation
This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Storage and Handling
Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Amino Acid Sequence
15 amino acids near the carboxy terminus of human PIKE.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Background
PIKE peptide is applicable as a control peptide for blocking antibody binding in Western blotting.

Antigen Details

Protein
PubMed

References & Citations

1. Reymond A, Meroni G, Fantozzi A, et al. The tripartite motif family identifies cell compartments. EMBO J. 2001; 20:2140-51. 2. Stremlau M, Owens CM, Perron MJ, et al. The cytoplasmic body component TRIM5? restricts HIV-1 infection in Old World monkeys. Nature 2004; 427:848-53. 3. Hatziioannou T, Perez-Caballero D, Yang A, et al. Retrovirus resistance factors REF1 and Lv1 are species-specific variants of TRIM5α. Proc. Nat’l. Acad. Sci. USA 2004; 101:10774-9 4. Xu L, Yang L, Moitra PK, et al. BTBD1 and BTBD2 colocalize to cytoplasmic bodies with the RBCC/tripartite motif protein, TRIM5?. Exp. Cell Res. 2003; 288:84-93.
Prod No.
Description
P212
P222
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok